SEC Form 4 · accession 0001678152-26-000003
BlossomHill Therapeutics, Inc. · BLSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason A Keyes
Officer — Chief Financial Officer
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 6:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001839970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | P | 700 | $16.00 | A | 700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $16.00 | Aug 6, 2026 | A | 56,746 | A | — | Aug 5, 2036 | Common Stock | 56,746 | 56,746 | D |
Explanation of responses
- F11/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.